Clinical Trials Logo

Subcutaneous Fat clinical trials

View clinical trials related to Subcutaneous Fat.

Filter by:

NCT ID: NCT06005441 Recruiting - Subcutaneous Fat Clinical Trials

A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.

Start date: November 10, 2023
Phase: Phase 2
Study type: Interventional

This is a randomized, placebo-controlled, Phase 2b study to evaluate the efficacy, safety, and tolerability of CBL-514 injection compared with CBL-A1 and CBL-A2 for reducing subcutaneous fat.

NCT ID: NCT05736107 Active, not recruiting - Subcutaneous Fat Clinical Trials

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

Start date: May 30, 2023
Phase: Phase 2
Study type: Interventional

This is a randomized, placebo-controlled, Phase 2b study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing subcutaneous fat.

NCT ID: NCT05234736 Completed - Subcutaneous Fat Clinical Trials

A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers

Start date: February 11, 2022
Phase: Phase 2
Study type: Interventional

This Phase 2 study will be an open-label and single course study to assess the safety, tolerability, PK and metabolite profile of CBL-514.

NCT ID: NCT04897412 Completed - Subcutaneous Fat Clinical Trials

A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)

Start date: February 14, 2022
Phase: Phase 2
Study type: Interventional

The Stage 2 of this phase 2 study will be a randomized, single-blind, placebo-controlled, parallel, and multiple-dose study to assess the efficacy, safety, and subject satisfaction of CBL-514.

NCT ID: NCT04699669 Completed - Subcutaneous Fat Clinical Trials

A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers

Start date: November 27, 2018
Phase: Phase 1
Study type: Interventional

The Phase 1 component of the study is a double-blind, placebo-controlled, single ascending dose (SAD) design intended to assess the safety, tolerability, and PK of CBL-514. The SAD part will involve 9 proposed dosing cohorts.

NCT ID: NCT04698642 Completed - Subcutaneous Fat Clinical Trials

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat

Start date: February 3, 2020
Phase: Phase 2
Study type: Interventional

The Phase 2a component of the study will be a randomized, open-label, parallel, and multiple dose study to further examine the safety and efficacy profile of 3 CBL-514 dose levels based on the results from Phase 1 of the study.

NCT ID: NCT04575467 Completed - Subcutaneous Fat Clinical Trials

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

Start date: December 9, 2020
Phase: Phase 2
Study type: Interventional

The Stage 1 of this phase 2 study is an open-label single ascending dose (SAD) study. The primary objectives are to evaluate the safety and tolerability of injection lipolysis with CBL-514. It will be followed by a parallel-arm multiple-dose design in Stage 2.

NCT ID: NCT04553627 Active, not recruiting - Subcutaneous Fat Clinical Trials

Feasibility of Producing the Appearance of a Gluteal Lift Post Cryolipolysis

Start date: July 15, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of cryolipolysis of the medial infragluteal fold to create the appearance of a gluteal lift.

NCT ID: NCT03871556 Completed - Subcutaneous Fat Clinical Trials

Diagnostic Ultrasound for Measuring Fat of the Body

Start date: March 20, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to provide information about human subcutaneous fat thickness at different anatomic sites on the body by measuring these thicknesses with a diagnostic ultrasound and also by correlating patient perceptions of body image with measured fat distribution. Subjects currently living in the Chicago metropolitan area and meet inclusion/exclusion criteria will be considered for enrollment.

NCT ID: NCT03682471 Completed - Subcutaneous Fat Clinical Trials

Long-term 24-month Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 (Sodium Deoxycholate Injection)

Start date: February 14, 2012
Phase:
Study type: Observational

The objective of this non-treatment, placebo-controlled, observational, 24-month follow-up study was to evaluate the long-term efficacy and safety of subcutaneous (SC) injections of deoxycholic acid (ATX-101) in the submental area. No treatment was administered in this study. Participants who previously received deoxycholic acid injections in studies ATX-101-10-16 [NCT01305577] or ATX-101-10-17 [NCT01294644] were enrolled in this non-treatment observational follow-up study to further evaluate safety and efficacy.